Yes, I would, Madam Chair. I would like to remind the committee that the identification of a gap in manufacturing capacity was the result of an analysis done in 2003. It became part of the strategic plan of the global enterprise. So considerable manufacturing capacity came on-stream between 2003 and 2009.
It's understandable that things have changed, and I think the decision to not proceed with the facility was the right one, although disappointing to everybody involved. But it gives us an important opportunity to re-invest in other areas that are important.
I would submit to the committee that probably the biggest gap in access of academic-based researchers to getting vaccine manufacturers for clinical trials is really due to the cost of it and not to whether there is a facility or not.